Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $57M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| sufentanil sublingual 30 mcg tablet | Phase 3 | Moderate-to-severe Acute Pain |
| Oral sufentanil | Phase 2 | Major Upper or Lower Abdominal Surgery |
| Sufentanil NanoTab PCA System/15 mcg | Phase 3 | Pain, Postoperative |
| Sufentanil NanoTab 20 mcg | Phase 2 | Acute Pain |
| morphine IV PCA | Phase 3 | Post-Operative Pain |
| sufentanil sublingual tablet 30 mcg | Phase 3 | Acute Moderate-to-severe Pain |
| Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) | Phase 2 | Sedation |
| Zalviso™ 15 mcg | Phase 3 | Moderate-to-severe Acute Pain |
| Sufentanil Tablet 30 mcg | Phase 3 | Post-Operative Pain |
| Sufentanil NanoTab | Phase 2 | Post Operative Pain |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.